Ventyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion

Reuters01-07

Eli Lilly is in advanced talks to buy Ventyx Biosciences, Inc. for more than $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Shares of Ventyx surged 62% in extended trading following the report, which said the deal could be announced imminently.

A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.

One of Ventyx's experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.

Eli Lilly told Reuters it does not "comment on business development activity", while Ventyx did not immediately respond to a request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601848785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601848785","market":"nz","top_or_hot":-1,"title":"Ventyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion","media":"Reuters","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a> is in advanced talks to buy  <a href=\"https://laohu8.com/S/VTYX\">Ventyx Biosciences, Inc.</a>  for more than $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.</p><p>Shares of Ventyx surged 62% in extended trading following the report, which said the deal could be announced imminently.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9ba7bc196b1c5c988824690085f96c55\" tg-width=\"355\" tg-height=\"104\"/></p><p>A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn&#39;s disease and ulcerative colitis to Lilly&#39;s pipeline, along with treatments for conditions like Parkinson&#39;s.</p><p>One of Ventyx&#39;s experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.</p><p>Eli Lilly told Reuters it does not &#34;comment on business development activity&#34;, while Ventyx did not immediately respond to a request for comment.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ventyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVentyx Biosciences Stock Soars 62% After Lilly in Talks to Buy Company for More Than $1 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 08:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a> is in advanced talks to buy  <a href=\"https://laohu8.com/S/VTYX\">Ventyx Biosciences, Inc.</a>  for more than $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.</p><p>Shares of Ventyx surged 62% in extended trading following the report, which said the deal could be announced imminently.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9ba7bc196b1c5c988824690085f96c55\" tg-width=\"355\" tg-height=\"104\"/></p><p>A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn&#39;s disease and ulcerative colitis to Lilly&#39;s pipeline, along with treatments for conditions like Parkinson&#39;s.</p><p>One of Ventyx&#39;s experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.</p><p>Eli Lilly told Reuters it does not &#34;comment on business development activity&#34;, while Ventyx did not immediately respond to a request for comment.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y71AX:1","article_id":"2601848785","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601848785","pubTimestamp":1767745652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 2-Lilly in talks to buy Ventyx Biosciences for more than $1 billion, WSJ reportsUpdates shares in paragraph 2, adds Eli Lilly's response in paragraph 5Jan 6  - Eli Lilly LLY.N is in advanced talks to buy Ventyx Biosciences VTYX.O for more than $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.Shares of Ventyx surged more than 50% in extended trading following the report, which said the deal could be announced imminently.A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.One of Ventyx's experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.Eli Lilly told Reuters it does not \"comment on business development activity\", while Ventyx did not immediately respond to a request for comment.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","VTYX":"Ventyx Biosciences, Inc."},"translate_title":"礼来公司洽谈以超过10亿美元收购Ventyx Biosciences股价飙升62%","themeId":"d9d938951d4e1d58a135a999ef2d5d12","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":1.97,"LLY":1.95},"content_text":"Eli Lilly is in advanced talks to buy  Ventyx Biosciences, Inc.  for more than $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.Shares of Ventyx surged 62% in extended trading following the report, which said the deal could be announced imminently.A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.One of Ventyx's experimental drugs is currently in mid-stage development for the treatment of a cardiovascular disease associated with obesity.Eli Lilly told Reuters it does not \"comment on business development activity\", while Ventyx did not immediately respond to a request for comment.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601848785","isCrawlerRequest":true}